Patents by Inventor Federica Del Monte

Federica Del Monte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES FOR USE IN THE DETECTION AND TREATMENT OF HEART DISEASE
    Publication number: 20230399387
    Abstract: The present disclosure is directed to method of diagnosing and treating heart disease using antibodies that bind to Cofilin, A? and/or Tau.
    Type: Application
    Filed: November 5, 2021
    Publication date: December 14, 2023
    Applicants: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Federica DEL MONTE, Rakez KAYED
  • Modulating phosphatase activity in cardiac cells
    Patent number: 11213534
    Abstract: Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve ?-adrenergic responsiveness.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: January 4, 2022
    Assignees: The University of Cincinnati, The General Hospital Corporation
    Inventors: Roger J. Hajjar, Federica del Monte, Evangelia Kranias
  • MODULATING PHOSPHATASE ACTIVITY IN CARDIAC CELLS
    Publication number: 20200171059
    Abstract: Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve ?-adrenergic responsiveness.
    Type: Application
    Filed: December 31, 2019
    Publication date: June 4, 2020
    Inventors: Roger J. Hajjar, Federica del Monte, Evangelia Kranias
  • MODULATING PHOSPHATASE ACTIVITY IN CARDIAC CELLS
    Publication number: 20200054652
    Abstract: Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve ?-adrenergic responsiveness.
    Type: Application
    Filed: April 11, 2019
    Publication date: February 20, 2020
    Inventors: Roger J. Hajjar, Federica Del Monte, Evangelia Kranias
  • MODULATING PHOSPHATASE ACTIVITY IN CARDIAC CELLS
    Publication number: 20180296578
    Abstract: Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve ?-adrenergic responsiveness.
    Type: Application
    Filed: March 9, 2016
    Publication date: October 18, 2018
    Applicants: The University of Cincinnati, The General Hospital Corporation, The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Roger J. Hajjar, Federica del Monte, Evangelia Kranias
  • Modulating phosphatase activity in cardiac cells
    Patent number: 9114148
    Abstract: Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve ?-adrenergic responsiveness.
    Type: Grant
    Filed: September 8, 2005
    Date of Patent: August 25, 2015
    Assignees: University of Cincinnati, The General Hospital Corporation
    Inventors: Roger J. Hajjar, Federica del Monte, Evangelia Kranias
  • Methods for treating restenosis
    Patent number: 8133878
    Abstract: Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent can be introduced into a blood vessel.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: March 13, 2012
    Assignee: The General Hospital Corporation
    Inventors: Roger J. Hajjar, Anne-Marie Lompr, Larissa Lipskaia, Federica del Monte
  • TREATING HEART FAILURE AND VENTRICULAR ARRHYTHMIAS
    Publication number: 20090239940
    Abstract: The present invention provides methods and materials for treating heart disorders, including heart failure and arrhythmia, by enhancing SERCA2a activity. Heart cells in a subject can be treated, for example, by introducing, into the heart of the subject, an adeno-associated virus subtype 6 (AAV6) viral delivery system that includes a functional nucleic acid encoding SERCA2a. For example, the functional nucleic acid encodes a non-viral therapeutic protein, thereby treating the subject.
    Type: Application
    Filed: February 23, 2009
    Publication date: September 24, 2009
    Inventors: Federica Del Monte, Roger J. Hajjar, Fabrice Prunier
  • Modulating Phosphatase Activity In Cardiac Cells
    Publication number: 20080125385
    Abstract: Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve ?-adrenergic responsiveness.
    Type: Application
    Filed: September 8, 2005
    Publication date: May 29, 2008
    Inventors: Roger J. Hajjar, Federica Del Monte, Evangelia Kranias
  • Methods of treating restenosis
    Patent number: 7291604
    Abstract: Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent can be introduced into a blood vessel.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: November 6, 2007
    Assignee: The General Hospital Corporation
    Inventors: Roger J. Hajjar, Anne-Marie Lompr, Larissa Lipskaia, Federica Del Monte
  • Methods of treating restenosis
    Publication number: 20050112101
    Abstract: Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent can be introduced into a blood vessel.
    Type: Application
    Filed: September 3, 2004
    Publication date: May 26, 2005
    Inventors: Roger Hajjar, Anne-Marie Lompr, Larissa Lipskaia, Federica Del Monte
  • Isolation procedure and optimized media solution to enhance long-term survival of cells
    Publication number: 20020110910
    Abstract: Isolation, enhanced yield, and maintenance (e.g., culture) methods for cells, e.g., cardiomyocytes, which maintain the structural and functional characteristics of freshly isolated cells are disclosed. Such methods can be used for developing long-term maintenance/cultures of cardiac myocytes which can be used in, for example, in vitro gene transfer, protein expression studies, and small molecule or drug screening, testing, toxicological study. Optimized media solutions to enhance long-term survival of acutely isolated cells are also provided.
    Type: Application
    Filed: November 21, 2001
    Publication date: August 15, 2002
    Applicant: Gwathmey, Inc.
    Inventors: Judith K. Gwathmey, Federica del Monte, Roger J. Hajjar, Georges E. Haddad